Spin On MannKind's Four-Week Delay For Afrezza Goes Both Ways
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if Afrezza is approved with a clean label, the product would face big commercial hurdles.
You may also be interested in...
MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.